William White
Hypertension Specialist · Farmington, CTNPI 1760489546
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,130,586 of the $2,138,138 with a category attached, or 99.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 16.6%.
Across 395 payments — averaging $5413.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$354K
- Sumitomo Pharma America, Inc.$342K
- Alnylam Pharmaceuticals Inc.$229K
- Takeda Pharmaceuticals U.S.A., Inc.$174K
- Jazz Pharmaceuticals Inc.$172K
- E.r. Squibb & Sons, L.L.C.$128K
- plus $738K from 21 others
Across 95 payments — averaging $6045.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$301K
- E.r. Squibb & Sons, L.L.C.$123K
- Bayer$38K
- Astrazeneca UK Limited$37K
- Novartis$29K
- Mylan Inc.$21K
- plus $26K from 4 others
What the payments were for
- Consulting fees$2,130,586100%
- Speaking & faculty fees$2,4410%
- Travel & lodging$4,1110%
- Food & beverage$1,0000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 55 | $354,060 |
| Sumitomo Pharma America, Inc. | 26 | $342,445 |
| Alnylam Pharmaceuticals Inc. | 43 | $229,050 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $174,432 |
| Jazz Pharmaceuticals Inc. | 46 | $172,173 |
| E.r. Squibb & Sons, L.L.C. | 19 | $127,563 |
| AstraZeneca | 30 | $126,445 |
| Astrazeneca UK Limited | 41 | $116,016 |
| Redhill Biopharma Inc. | 6 | $93,504 |
| Travere Therapeutics, Inc. | 26 | $84,500 |
| UCB Biosciences Inc. | 4 | $60,870 |
| Sanofi US Services Inc. | 8 | $44,919 |
| AbbVie(2 entities) | 13 | $38,251 |
| Lundbeck LLC | 5 | $21,990 |
| AMAG Pharmaceuticals, Inc. | 1 | $20,963 |
| Medtronic(2 entities) | 2 | $17,940 |
| Beigene USA, Inc. | 5 | $17,713 |
| Vertex | 6 | $17,288 |
| Sunovion Pharmaceuticals Inc. | 3 | $16,738 |
| Eisai Inc. | 1 | $16,298 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $12,775 |
| Ironwood Pharmaceuticals, Inc | 1 | $9,919 |
| Tersera Therapeutics LLC | 1 | $9,281 |
| Astellas Pharma Global Development | 2 | $5,000 |
| Bayer | 1 | $4,713 |
| F. Hoffmann-la Roche AG | 1 | $2,441 |
| Novartis | 3 | $855 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hypertension specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Other hypertension specialist in Farmington
- Beatriz Esayag-TendlerFarmington$46
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.